Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the ...

Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling ...

This article explores methods to enhance efficiency in the drug discovery and development pipeline, focusing on optimizing ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

Objective—Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic β- and α-cells. Previous studies have focused on the improvements in β-cell function ...

Low-density lipoproteins (LDL)—commonly known as bad cholesterol—have long been on scientists' radar as a major contributor ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

Low-density lipoproteins (LDL) -- commonly known as bad cholesterol -- have long been on scientists' radar as a major contributor to heart disease. But these microscopic troublemakers have hidden ...

Monoclonal antibodies, or mAbs, are important tools in medicine. These laboratory-made proteins are widely used in treatments ...